Alberto Mantovani, MD, is Emeritus Professor of Pathology at the Humanitas University in Milan, Emeritus Scientific Director of the Istituto Clinico Humanitas and Chair of Inflammation and Therapeutic Innovation, William Harvey Research Institute, Queen Mary University, London, UK. His attention has been focused on molecular mechanisms of innate immunity and inflammation and on the role in the tumor microenvironment and cancer progression of tumor-associated macrophages (TAM). He has contributed to the advancement of knowledge in the field of Immunology formulating new paradigms and identifying new molecules and functions. More recently he focused on COVID-19, contributing to the identification of genetic associations and of a novel severity biomarker.

He has recently been elected as member of the National Academy of Sciences of the US. For his research activity he has received several national and international awards, such as the Triennial OECI Award from the Organization of the European Cancer Institutes, the Robert Koch Award for his contribution to tumor immunology and immunotherapy, the American-Italian Cancer Foundation (AICF) Prize for Excellence in Medicine, the American Association for Cancer Research International Pezcoller Award for Extraordinary Achievement in Cancer Research, the Cancer Immunotherapy Association - CIMT Lifetime Achievement Award, the Lifetime Achievement in Inflammation Award by the International Association of Inflammation Societies (IAIS); Sir Hans Krebs Medal by the Federation of the European Biochemical Societies and, most recent, “Lombardia è Ricerca” Prize (1M Euros), international Jury, international awardees (2024).

The broad impact of his contributions is testified by citations. As of February 2025 he has over 182,000 citations and an H-index of 191 according to Scopus, over 277,000 and 227 according to Google Scholar.

Prof. Dr. Med. Alberto Mantovani